Vogenx (NASDAQ:VOGX) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Vogenx (NASDAQ:VOGX) posted its earnings results on Friday. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, Zacks reports.

Vogenx Price Performance

Shares of VOGX stock traded down $0.78 during trading hours on Friday, reaching $17.45. 66,333 shares of the stock traded hands, compared to its average volume of 100,289. The firm has a fifty day moving average of $23.45. Vogenx has a 1-year low of $12.95 and a 1-year high of $38.41. The firm has a market capitalization of $259.13 million and a price-to-earnings ratio of -249.29.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on VOGX. WBB Securities assumed coverage on Vogenx in a research note on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 price target on the stock. Zacks Research upgraded Vogenx to a “hold” rating in a report on Monday, September 28th. JonesTrading started coverage on Vogenx in a research report on Tuesday, September 1st. They issued a “buy” rating and a $55.00 target price for the company. Finally, Wall Street Zen raised shares of Vogenx to a “hold” rating in a research report on Saturday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $48.50.

About Vogenx

Vogenx, Inc is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company has historically concentrated on small-molecule drug candidates intended to address conditions in which existing treatment options may be limited.

Vogenx’s lead development program has included VGX-1027, an investigational anti-inflammatory compound studied for its potential to regulate abnormal immune responses. Research involving the candidate has focused on diseases associated with inflammation and immune-system dysfunction, although its development status and commercial availability may change over time.

The company’s activities have primarily involved pharmaceutical research and development rather than the marketing of an established portfolio of products.